BB Biotech Ventures

What they do

Originally established in 1993 as BB Biotech Ventures under the Bellevue Group, the firm relaunched its venture capital strategy in 2018 as Pureos Bioventures. The firm is positioned as one of the largest institutional Swiss VC funds solely dedicated to private biotech companies. Pureos is highly distinctive for its deep scientific expertise, active company-building approach, and strict focus on novel biological drugs, nucleic acids, and cell/gene therapies. They have a strong reputation in the European ecosystem for bridging the local funding gap and successfully guiding academic spin-offs to clinical stages and public markets.

What they look for

Pureos Bioventures invests exclusively in private, innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. They strive to impact patients' lives by advancing innovative treatments for severe diseases. They explicitly look for scientific excellence, strong founding teams, and therapies addressing devastating diseases with high unmet medical needs. They are highly supportive of driven academic founders (PhDs and postdocs) who are eager to transition into the entrepreneurial world.

Stage

Seed, Series A

Sectors

Healthcare, Deeptech

Based

Pfäffikon, CH